430 related articles for article (PubMed ID: 15632701)
1. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production.
Kojima M; Ito T; Oono T; Hisano T; Igarashi H; Arita Y; Kawabe K; Coy DH; Jensen RT; Nawata H
Pancreas; 2005 Jan; 30(1):62-70. PubMed ID: 15632701
[TBL] [Abstract][Full Text] [Related]
2. VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis.
Yadav M; Huang MC; Goetzl EJ
Cell Immunol; 2011; 267(2):124-32. PubMed ID: 21295288
[TBL] [Abstract][Full Text] [Related]
3. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells.
Delgado M; Robledo G; Rueda B; Varela N; O'Valle F; Hernandez-Cortes P; Caro M; Orozco G; Gonzalez-Rey E; Martin J
Arthritis Rheum; 2008 Apr; 58(4):1010-9. PubMed ID: 18383379
[TBL] [Abstract][Full Text] [Related]
4. Anti-hyperglycemic, antioxidant and anti-inflammatory effects of VIP and a VPAC1 agonist on streptozotocin-induced diabetic mice.
Yu R; Zhang H; Huang L; Liu X; Chen J
Peptides; 2011 Feb; 32(2):216-22. PubMed ID: 21129425
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
[TBL] [Abstract][Full Text] [Related]
6. cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells.
Nagata A; Tanaka T; Minezawa A; Poyurovsky M; Mayama T; Suzuki S; Hashimoto N; Yoshida T; Suyama K; Miyata A; Hosokawa H; Nakayama T; Tatsuno I
J Cell Physiol; 2009 Oct; 221(1):75-83. PubMed ID: 19496170
[TBL] [Abstract][Full Text] [Related]
7. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
Cunha-Reis D; Ribeiro JA; Sebastião AM
Brain Res; 2005 Jul; 1049(1):52-60. PubMed ID: 15935995
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of vasoactive intestinal peptide-elicited coronary vasodilation in the isolated perfused rat heart.
Sawmiller DR; Ashtari M; Urueta H; Leschinsky M; Henning RJ
Neuropeptides; 2006 Oct; 40(5):349-55. PubMed ID: 17030371
[TBL] [Abstract][Full Text] [Related]
9. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies.
Delgado M; Pozo D; Martinez C; Leceta J; Calvo JR; Ganea D; Gomariz RP
J Immunol; 1999 Feb; 162(4):2358-67. PubMed ID: 9973516
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts.
Juarranz Y; Gutiérrez-Cañas I; Santiago B; Carrión M; Pablos JL; Gomariz RP
Arthritis Rheum; 2008 Apr; 58(4):1086-95. PubMed ID: 18383383
[TBL] [Abstract][Full Text] [Related]
11. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
12. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
[TBL] [Abstract][Full Text] [Related]
13. Location and function of VPAC1, VPAC2 and NPR-C receptors in VIP-induced vasodilation of porcine basilar arteries.
Grant S; Lutz EM; McPhaden AR; Wadsworth RM
J Cereb Blood Flow Metab; 2006 Jan; 26(1):58-67. PubMed ID: 15959462
[TBL] [Abstract][Full Text] [Related]
14. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis.
Sun W; Hong J; Zang YC; Liu X; Zhang JZ
Int Immunol; 2006 Dec; 18(12):1691-700. PubMed ID: 17077178
[TBL] [Abstract][Full Text] [Related]
15. Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients.
Burian B; Storka A; Marzluf BA; Yen YC; Lambers C; Robibaro B; Vonbank K; Mosgoeller W; Petkov V
Peptides; 2010 Apr; 31(4):603-8. PubMed ID: 20026142
[TBL] [Abstract][Full Text] [Related]
16. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor.
Voice JK; Dorsam G; Lee H; Kong Y; Goetzl EJ
FASEB J; 2001 Nov; 15(13):2489-96. PubMed ID: 11689474
[TBL] [Abstract][Full Text] [Related]
17. Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation.
St Hilaire RC; Murthy SN; Kadowitz PJ; Jeter JR
Peptides; 2010 Aug; 31(8):1517-22. PubMed ID: 20452385
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of vasoactive intestinal peptide and altered expression of its receptors in rat diabetic cardiomyopathy.
Dvoráková MC; Pfeil U; Kuncová J; Svíglerová J; Galvis G; Krasteva G; König P; Grau V; Slavíková J; Kummer W
Cell Tissue Res; 2006 Mar; 323(3):383-93. PubMed ID: 16344947
[TBL] [Abstract][Full Text] [Related]
19. Contribution of vasoactive intestinal peptide to immune homeostasis in trophoblast-maternal leukocyte interaction under LPS stimulation.
Fraccaroli L; Grasso E; Hauk V; Cortelezzi M; Pérez Leirós C; Ramhorst R
Neuroimmunomodulation; 2014; 21(1):21-30. PubMed ID: 24135863
[TBL] [Abstract][Full Text] [Related]
20. Role of VPAC2 receptor in monocrotaline-induced pulmonary hypertension in rats.
Koga M; Mizuno Y; Watanabe I; Kawakami H; Goto T
J Appl Physiol (1985); 2014 Aug; 117(4):383-91. PubMed ID: 24947028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
